DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 2: C-terminal benzimidazoles and derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 5, 2004, Pages 1259-1263

  Bürli, Roland W ^a   Jones, Peter ^a   McMinn, Dustin ^a   Le, Quan ^a   Duan, Jian Xin ^a   Kaizerman, Jacob A ^a   Difuntorum, Stacey ^a   Moser, Heinz E ^a  

^a Genesoft Pharmaceuticals Inc   (United States)

Author keywords

Antibiotics; DNA binder; Lead optimization; Minor groove

Indexed keywords

AMIDE; ANTIINFECTIVE AGENT; BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; LIGAND; PYRROLE;

AMINO TERMINAL SEQUENCE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CARBOXY TERMINAL SEQUENCE; CHEMICAL BOND; CONTROLLED STUDY; DNA BINDING; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ELECTRICITY; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; LIGAND BINDING; MOLECULE; NONHUMAN; PARAMETER; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

ESCHERICHIA COLI; NEGIBACTERIA; POSIBACTERIA;

EID: 1242339013     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.12.043     Document Type: Article

References (15)

1. McDevitt D., Rosenberg M. TRENDS in Microbiology. 9:2001;611. and references cited therein.
2. Projan S.J., Youngman P.J. Curr. Opin. Microbiology. 5:2002;463.
3. Bürli R.W., Ge Y., White S., Baird E.E., Touami S.M., Taylor M., Kaizerman J.A., Moser H.E. Bioorg. Med. Chem. Lett. 12:2002;2591.
4. Kaizerman J.A., Gross M.I., Ge Y., White S., Hu W., Duan J.X., Baird E.E., Johnson K.W., Tanaka R.D., Moser H.E., Bürli R.W. J. Med. Chem. 46:2003;3914.
5. Bürli, R.; McMinn, D.; Kaizerman, J.; Hu, W.; Pack, Q.; Le, Q.; Ge, Y.; Gross, M.; Difuntorum, S.; Moser, H. Bioorg. Med. Chem. Lett., submitted.
6. Bremer R.E., Szewczyk J.W., Baird E.E., Dervan P.B. Bioorg. Med. Chem. 8:2000;1947.
7. 2 (1 atm) at 25°C for 12 h, and filtered through Celite. The filtrate was evaporated and the residue dissolved in AcOEt (200 mL), and treated with HCl gas. Evaporation of solvents gave amino pyrrole 3 (8.05 g, 91%).
8. Dudouit F., Goossens J.-F., Houssin R., Henichart J.-P., Colson P., Houssier C., Gelus N., Bailly C. Bioorg. Med. Chem. Lett. 10:2000;553.
9. Baird E.E., Dervan P.B. J. Am. Chem. Soc. 118:1996;6141.
10. 2O resulted in precipitation of 10, which was collected by filtration and dried (→7.82 g, 52%).
11. 1H NMR and mass spectrometry and showed purity of at least 90%. The isolated yields after HPLC purification ranged from ca. 10-30%.
12. Bremer R.E., Wurtz N.R., Szewczyk J.W., Dervan P.B. Bioorg. Med. Chem. 9:2001;2093.
13. +). Purity (analyt. HPLC, 310 nm) 95%.
14. Bruice T.C., Mei H.-Y., He G.-X., Lopez V. Proc. Natl. Acad. Sci. U.S.A. 89:1992;1700.
15. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 5th ed; Approved Standard (M7A5); National Committee for Clinical Laboratory Standards, Wayne, PA, 2000.